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Totally biological valved conduits like the Shelhigh No-React implant were expected to offer 28 
several advantages for patients requiring aortic root replacement in whom a tissue valve would 29 
be the preferential option. The stentless design of the valve promised a better hemodynamic 30 
performance following implantation of a stented valve. Furthermore traditionally glutaraldehyde-31 
preserved biological valves tended to calcify, especially in younger patients, whereas the novel 32 
No-React detoxification process promised to ensure stable tissue cross-linking, resulting in 33 
less calcification and tissue deterioration. This was demonstrated in the animal model (1). 34 
Finally, availability of the conduit from the bench in the most commonly used sizes as opposed 35 
to self-constructed valved tubes and homografts is considered as additional advantage.  36 
In this paper, the group of Zürich’s University Hospital reports additional conflicting mid- 37 
to long-term results following implantation of the former Shelhigh conduit in aortic root ± 38 
ascending aortic position (2). Their initial experience, like ours and that of other groups, 39 
was satisfying regarding the implantability of the graft, the postoperative hemodynamics 40 
and the short-term clinical results (3,4). More than 15 years ago, we optimistically 41 
implanted this graft when a tissue valve was found to be the best solution for patients 42 
requiring aortic root replacement. Years ago, we were the first group to describe some 43 
negative experience with the Shelhigh conduit since several patients presented with 44 
sudden disintegration of the graft, leading to unexpected severe complications that 45 
required most difficult redo-operations (5). Unfortunately, we were not able to find which 46 
patients may be at increased risk for such complications: no statistical significant 47 
relationship was found regarding the timing of the operation (planned versus emergency) 48 
nor regarding the underlying pathology (aortic root dilation, acute type A aortic dissection 49 
or aortic valve endocarditis with destruction of the aortic root) or the implantation 50 
technique (interrupted versus continuous sutures). Review of the literature revealed that 51 
other institutions have observed similar singular cases.  52 
The present analysis by the Zürich’s group confirms our observations and reports similar mid- to 53 
long-term adverse outcome with a relatively high rate of premature death, “a very high rate of 54 
reoperations due to endocarditis, aorto-ventricular disconnection and structural valve failure” (2). 55 
The authors concluded that this may be potentially connected to the nature of the conduit. In 56 
fact looking at the details of this small series, there are several patients that died because of 57 
what the authors called unoperable intraoperative status. A similar case report was published by 58 
Tjan et al. from Münster, where the only solution to the uncontrollable intraoperative situation, 59 
was the removal of the whole heart and the construction of a bi-ventricular assist device as a 60 
bridge to transplantation (6). We have fortunately never encoutered an unoperable 61 
intraoperative situs although the amount of destruction of the aortic root was surprising and 62 
technically extremely challenging in all cases we had to re-operate.  63 
  64 
In that sense, these observations are in line with other reports: the summarized experience of 65 
Calderon presented at the meeting of the Society of Heart Valves Diseases a series of 51 66 
consecutive patients who received the Shelhigh conduit, with a reoperation rate of 13% (7/51) 67 
after Shelhigh conduit implants (7). All patients of this series demonstrated a similar finding to 68 
that described by the Zürich group, with a disintegration of the proximal anastomosis at the level 69 
of the aortic annulus within one year after implantation. The intraoperative findings were very 70 
similar with pseudo-aneurysmal formation and sterile abscess formation. Another group in the 71 
Netherlands published a similar experience in 2011 (8). 72 
Extensive work from a Munich group has independently focused on the No-React® patch from 73 
the same provider and used for pericardial closure in 127 patients. Also in this location, a high 74 
incidence of sterile abscess formation was found. Bacterial growth was never found and the 75 
underlying mechanism of abscess formation was suspected to be a xenogenic complement 76 
mediated graft rejection (9).  77 
To share our experience, we exchanged intensively with the dutch group and presented our 78 
common results at the 2015 EACTS meeting (10). The series included 291 consecutive patients 79 
with a mean age of 69 years. During a mean follow-up of 70.3 ± 53.1 months, 29 patients 80 
(11.1%) died from unkown reasons and the overall rate of re-operation of 8.6% (25 patients) 81 
was worrisome. We found similar causes leading to re-operation: infection of the conduit (n=9), 82 
aorto-ventricular disconnection (n=4), pseudo-aneurysm formation (n=4) and structural valve 83 
degeneration (n=8).  84 
The results presented by the Zurich group are even worse than ours with a re-operation rate 85 
close to 20% and a surprisingly high rate of unexplained deaths. For all centers that have 86 
implanted the Shelhigh conduit, we strongly recommend long-term follow-up, especially in 87 
asymptomatic patients, since unexpected findings may be observed independently of structural 88 
valve degeneration. 89 
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